Cargando…

Tumor-derived exosomes: the next generation of promising cell-free vaccines in cancer immunotherapy

Identification of immunogenic tumor antigens that are efficiently processed and delivered by dendritic cells to prime the immune system and to induce an appropriate immune response is a research hotspot in the field of cancer vaccine development. High biosafety is an additional demand. Tumor-derived...

Descripción completa

Detalles Bibliográficos
Autores principales: Naseri, Marzieh, Bozorgmehr, Mahmood, Zöller, Margot, Ranaei Pirmardan, Ehsan, Madjd, Zahra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7466856/
https://www.ncbi.nlm.nih.gov/pubmed/32934883
http://dx.doi.org/10.1080/2162402X.2020.1779991
_version_ 1783577904209199104
author Naseri, Marzieh
Bozorgmehr, Mahmood
Zöller, Margot
Ranaei Pirmardan, Ehsan
Madjd, Zahra
author_facet Naseri, Marzieh
Bozorgmehr, Mahmood
Zöller, Margot
Ranaei Pirmardan, Ehsan
Madjd, Zahra
author_sort Naseri, Marzieh
collection PubMed
description Identification of immunogenic tumor antigens that are efficiently processed and delivered by dendritic cells to prime the immune system and to induce an appropriate immune response is a research hotspot in the field of cancer vaccine development. High biosafety is an additional demand. Tumor-derived exosomes (TEXs) are nanosized lipid bilayer encapsulated vesicles that shuttle bioactive information to the tumor microenvironment facilitating tumor progression. However, accumulating evidence points toward the capacity of TEXs to efficiently stimulate immune responses against tumors provided they are appropriately administered. After briefly describing the function of exosomes in cancer biology and their communication with immune cells, we summarize in this review in vitro and preclinical studies eliciting the potency of TEXs in inducing effective anti-tumor responses and recently modified strategies further improving TEX-vaccination efficacy. We interpret the available data as TEXs becoming a lead in cancer vaccination based on tumor antigen-selective high immunogenicity.
format Online
Article
Text
id pubmed-7466856
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-74668562020-09-14 Tumor-derived exosomes: the next generation of promising cell-free vaccines in cancer immunotherapy Naseri, Marzieh Bozorgmehr, Mahmood Zöller, Margot Ranaei Pirmardan, Ehsan Madjd, Zahra Oncoimmunology Review Identification of immunogenic tumor antigens that are efficiently processed and delivered by dendritic cells to prime the immune system and to induce an appropriate immune response is a research hotspot in the field of cancer vaccine development. High biosafety is an additional demand. Tumor-derived exosomes (TEXs) are nanosized lipid bilayer encapsulated vesicles that shuttle bioactive information to the tumor microenvironment facilitating tumor progression. However, accumulating evidence points toward the capacity of TEXs to efficiently stimulate immune responses against tumors provided they are appropriately administered. After briefly describing the function of exosomes in cancer biology and their communication with immune cells, we summarize in this review in vitro and preclinical studies eliciting the potency of TEXs in inducing effective anti-tumor responses and recently modified strategies further improving TEX-vaccination efficacy. We interpret the available data as TEXs becoming a lead in cancer vaccination based on tumor antigen-selective high immunogenicity. Taylor & Francis 2020-06-16 /pmc/articles/PMC7466856/ /pubmed/32934883 http://dx.doi.org/10.1080/2162402X.2020.1779991 Text en © 2020 The Author(s). Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Naseri, Marzieh
Bozorgmehr, Mahmood
Zöller, Margot
Ranaei Pirmardan, Ehsan
Madjd, Zahra
Tumor-derived exosomes: the next generation of promising cell-free vaccines in cancer immunotherapy
title Tumor-derived exosomes: the next generation of promising cell-free vaccines in cancer immunotherapy
title_full Tumor-derived exosomes: the next generation of promising cell-free vaccines in cancer immunotherapy
title_fullStr Tumor-derived exosomes: the next generation of promising cell-free vaccines in cancer immunotherapy
title_full_unstemmed Tumor-derived exosomes: the next generation of promising cell-free vaccines in cancer immunotherapy
title_short Tumor-derived exosomes: the next generation of promising cell-free vaccines in cancer immunotherapy
title_sort tumor-derived exosomes: the next generation of promising cell-free vaccines in cancer immunotherapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7466856/
https://www.ncbi.nlm.nih.gov/pubmed/32934883
http://dx.doi.org/10.1080/2162402X.2020.1779991
work_keys_str_mv AT naserimarzieh tumorderivedexosomesthenextgenerationofpromisingcellfreevaccinesincancerimmunotherapy
AT bozorgmehrmahmood tumorderivedexosomesthenextgenerationofpromisingcellfreevaccinesincancerimmunotherapy
AT zollermargot tumorderivedexosomesthenextgenerationofpromisingcellfreevaccinesincancerimmunotherapy
AT ranaeipirmardanehsan tumorderivedexosomesthenextgenerationofpromisingcellfreevaccinesincancerimmunotherapy
AT madjdzahra tumorderivedexosomesthenextgenerationofpromisingcellfreevaccinesincancerimmunotherapy